Neonatal SHIV infection in rhesus macaques elicited heterologous HIV-1-neutralizing antibodies.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
28 03 2023
Historique:
received: 15 10 2022
revised: 21 12 2022
accepted: 28 02 2023
medline: 3 4 2023
pubmed: 17 3 2023
entrez: 16 3 2023
Statut: ppublish

Résumé

Infants and children infected with human immunodeficiency virus (HIV)-1 have been shown to develop neutralizing antibodies (nAbs) against heterologous HIV-1 strains, characteristic of broadly nAbs (bnAbs). Thus, having a neonatal model for the induction of heterologous HIV-1 nAbs may provide insights into the mechanisms of neonatal bnAb development. Here, we describe a neonatal model for heterologous HIV-1 nAb induction in pathogenic simian-HIV (SHIV)-infected rhesus macaques (RMs). Viral envelope (env) evolution showed mutations at multiple sites, including nAb epitopes. All 13 RMs generated plasma autologous HIV-1 nAbs. However, 8/13 (62%) RMs generated heterologous HIV-1 nAbs with increasing potency over time, albeit with limited breadth, and mapped to multiple nAb epitopes, suggestive of a polyclonal response. Moreover, plasma heterologous HIV-1 nAb development was associated with antigen-specific, lymph-node-derived germinal center activity. We define a neonatal model for heterologous HIV-1 nAb induction that may inform future pediatric HIV-1 vaccines for bnAb induction in infants and children.

Identifiants

pubmed: 36924501
pii: S2211-1247(23)00266-8
doi: 10.1016/j.celrep.2023.112255
pmc: PMC10117998
mid: NIHMS1887308
pii:
doi:

Substances chimiques

Broadly Neutralizing Antibodies 0
HIV Antibodies 0
Antibodies, Neutralizing 0
Epitopes 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

112255

Subventions

Organisme : NIAID NIH HHS
ID : P01 AI048280
Pays : United States
Organisme : NIAID NIH HHS
ID : P30 AI064518
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI140897
Pays : United States
Organisme : NIAID NIH HHS
ID : UC6 AI058607
Pays : United States
Organisme : NIMH NIH HHS
ID : P01 MH105303
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201800004C
Pays : United States

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Références

J Virol. 2018 Aug 16;92(17):
pubmed: 29950423
Nat Immunol. 2019 Feb;20(2):163-172
pubmed: 30643263
Cell Rep Med. 2021 Jun 15;2(6):100314
pubmed: 34195680
Cell Rep. 2018 Oct 23;25(4):893-908.e7
pubmed: 30355496
Science. 2019 Dec 6;366(6470):
pubmed: 31806786
Elife. 2021 Sep 17;10:
pubmed: 34533134
Immunity. 2016 Jul 19;45(1):31-45
pubmed: 27438765
Sci Transl Med. 2014 Sep 3;6(252):252ra120
pubmed: 25186175
Science. 2021 Jan 8;371(6525):
pubmed: 33214287
J Virol. 2019 Jul 17;93(15):
pubmed: 31092583
J Int AIDS Soc. 2021 Nov;24 Suppl 7:e25831
pubmed: 34806332
J Virol. 2020 Mar 17;94(7):
pubmed: 31941772
J Virol. 2008 Dec;82(24):12449-63
pubmed: 18842730
Immunol Rev. 2013 Jul;254(1):326-42
pubmed: 23772629
Nat Med. 2014 Jun;20(6):583-5
pubmed: 24901564
Sci Transl Med. 2019 Oct 30;11(516):
pubmed: 31666399
J Virol. 1999 Jul;73(7):5466-72
pubmed: 10364294
Sci Transl Med. 2016 Sep 28;8(358):358ra125
pubmed: 27683550
Immunity. 2015 Nov 17;43(5):959-73
pubmed: 26588781
J Exp Med. 2011 Oct 24;208(11):2237-49
pubmed: 21987658
J Immunol Methods. 2014 Jul;409:131-46
pubmed: 24291345
Proc Natl Acad Sci U S A. 2016 Mar 8;113(10):2702-7
pubmed: 26908875
Science. 2011 Nov 25;334(6059):1097-103
pubmed: 21998254
Immunity. 2013 Jan 24;38(1):176-86
pubmed: 23313589
Immunol Rev. 2017 Jan;275(1):145-160
pubmed: 28133802
J Virol. 2013 Feb;87(3):1554-68
pubmed: 23175357
J Exp Med. 2000 Dec 4;192(11):1553-62
pubmed: 11104798
Cell Host Microbe. 2014 Aug 13;16(2):215-226
pubmed: 25121750
Methods Mol Biol. 2009;485:395-405
pubmed: 19020839
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
J Virol. 2019 Feb 5;93(4):
pubmed: 30429339
Science. 2009 Oct 9;326(5950):285-9
pubmed: 19729618
Sci Immunol. 2016 Jul 29;1(1):aag0851
pubmed: 28783677
Clin Vaccine Immunol. 2015 Dec 09;23(2):84-94
pubmed: 26656117
Sci Transl Med. 2017 Mar 15;9(381):
pubmed: 28298420
Elife. 2020 Oct 21;9:
pubmed: 33084569
J Immunol. 2016 Aug 1;197(3):994-1002
pubmed: 27335502
Cell Rep. 2019 Nov 12;29(7):1756-1766.e8
pubmed: 31722194
Cell Rep. 2020 Feb 4;30(5):1553-1569.e6
pubmed: 32023469
J Virol. 2021 Mar 3;95(11):
pubmed: 33658341
Nat Commun. 2018 Mar 28;9(1):1251
pubmed: 29593217
Nat Med. 2014 Jun;20(6):655-8
pubmed: 24859529
AIDS. 2014 Jan 14;28(2):163-9
pubmed: 24361678
J Virol. 2007 Aug;81(16):8827-32
pubmed: 17537848
Cell. 2021 May 27;184(11):2955-2972.e25
pubmed: 34019795
Cell. 2018 Oct 4;175(2):387-399.e17
pubmed: 30270043
J Immunol. 2009 Nov 15;183(10):6513-21
pubmed: 19841192
Science. 2017 Mar 17;355(6330):1129-1130
pubmed: 28302812
Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):E3413-22
pubmed: 27247400
J Virol. 2014 Mar;88(5):2489-507
pubmed: 24352443
Cell Rep. 2017 Feb 28;18(9):2175-2188
pubmed: 28249163
J Virol. 2003 Feb;77(4):2736-40
pubmed: 12552014
Cell Rep. 2019 Feb 5;26(6):1627-1640.e7
pubmed: 30726743
Cell Rep. 2017 Dec 26;21(13):3681-3690
pubmed: 29281818
J Virol. 2006 May;80(10):5074-7
pubmed: 16641299
Immunity. 2014 Dec 18;41(6):909-18
pubmed: 25526306
Nat Biotechnol. 2012 May 07;30(5):423-33
pubmed: 22565972
Cytokine Growth Factor Rev. 2017 Oct;37:1-16
pubmed: 28455216
Blood. 2010 Nov 25;116(22):4404-14
pubmed: 20616217
Nature. 2014 May 1;509(7498):55-62
pubmed: 24590074
PLoS One. 2016 Apr 27;11(4):e0154253
pubmed: 27119555
Nat Struct Mol Biol. 2016 Jan;23(1):81-90
pubmed: 26689967
J Virol. 2014 Jul;88(14):7715-26
pubmed: 24807721
Nature. 2013 Apr 25;496(7446):469-76
pubmed: 23552890
Cell. 2016 Jun 30;166(1):77-87
pubmed: 27345369
J Virol. 2017 Oct 13;91(21):
pubmed: 28794027
Front Immunol. 2018 Sep 12;9:1975
pubmed: 30258437

Auteurs

Bhavna Hora (B)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.

Hui Li (H)

Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Xiaoying Shen (X)

Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.

Mitchell Martin (M)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.

Yue Chen (Y)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.

Madison Berry (M)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.

Tyler Evangelous (T)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.

Andrew N Macintyre (AN)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.

Aria Arus-Altuz (A)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.

Shuyi Wang (S)

Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Ajay Singh (A)

Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Chengyan Zhao (C)

Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Nicole De Naeyer (N)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.

Todd DeMarco (T)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.

Cindy Kuykendall (C)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.

Thaddeus Gurley (T)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.

Kevin O Saunders (KO)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA.

Thomas Denny (T)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.

M Anthony Moody (MA)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.

John Misamore (J)

BIOQUAL, Inc., Rockville, MD 20850, USA.

Mark G Lewis (MG)

BIOQUAL, Inc., Rockville, MD 20850, USA.

Kevin Wiehe (K)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.

Derek W Cain (DW)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA.

David C Montefiori (DC)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.

George M Shaw (GM)

Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.

Wilton B Williams (WB)

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: wilton.williams@duke.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH